ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Cmax"

  • Abstract Number: 0509 • ACR Convergence 2021

    Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

    Anjaneya Chimalakonda1, James Burke1, Lihong Cheng1, Ian Catlett1, Michael Tagen1, Qihong Zhao1, Aditya Patel1, Jun Shen1, Ihab Girgis1, Subhashis Banerjee1 and John Throup2, 1Bristol Myers Squibb, Princeton, NJ, 2Bristol Myers Squibb, Princeton

    Background/Purpose: Deucravacitinib is a novel, oral, allosteric agent that selectively inhibits intracellular signaling by binding to the tyrosine kinase 2 (TYK2) pseudokinase domain rather than…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences